



PATENT CLAIMS

1. The salt of diclofenac (2-[2,6-dichlorophenyl]-amino]-benzeneacetic acid) with a cyclic organic base having the general formula (I)



10 in which X is a group of the formula  $(CH_2)_m$ , in which m is 0 or 1 or 2, or X is oxygen or S or NR, in which R is an alkyl group  $C_1-C_4$ , and n is 2 or 3.

2. A process for preparing the salt of diclofenac (2-[2,6-dichlorophenyl]-amino]-benzeneacetic acid) with a cyclic organic base having the general formula (I)



20 in which X is a group of the formula  $(CH_2)_m$ , in which m is 0 or 1 or 2, or X is oxygen or S or NR, in which R is an alkyl group  $C_1-C_4$ , and n is 2 or 3, characterised by dissolving the diclofenac in a suitable organic solvent, adding said cyclic organic base, reacting said compounds together, removing the solvent and crystallising the product obtained.

- a 3. A process as claimed in claim 2, <sup>wherein</sup> ~~characterised in that~~ said solvent is acetone, ethanol or chloroform.


- a 25 4. A process as claimed in claim 2, <sup>wherein</sup> ~~characterised in that~~ the cyclic organic base (I) is added in equimolar quantity or in slight excess with respect to the diclofenac.

- a 5. A process as claimed in claim 2, <sup>wherein</sup> ~~characterised in that~~ said reaction is conducted at ambient temperature under agitation for a time of 30 between 0.5 and 3 hours.

- a 6. A process as claimed in claim 2, <sup>wherein</sup> ~~characterised in that~~ the solvent is removed by distillation under vacuum at a temperature of between 35 and 45°C.

*a* 7. A process as claimed in claim 2, <sup>wherein</sup> ~~characterised in that~~ said crystallisation is implemented by treating the solvent removal residue with hexane or petroleum ether under energetic agitation.

*Ent 22* 8. Pharmaceutical compositions containing therapeutically active quantities of the salt of diclofenac with a cyclic organic base having the general formula (I)



in which X is a group of the formula  $(CH_2)_m$ , in which m is 0 or 1 or 2, or X is oxygen or S or NR, in which R is an alkyl group  $C_1-C_4$ , and n is 2 or 3, together with pharmaceutically acceptable excipients.

9. Compositions as claimed in claim 8, characterised by containing a quantity of the salt of diclofenac with said cyclic organic base corresponding to 10-200 mg of diclofenac per unit dosage.

10. Compositions as claimed in claim 8, characterised by being prepared in granular form and packaged into water-impermeable sachets, to be dissolved in a little water to form a solutions for oral administration.

*Paul*  
*a 3*